{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:08:24Z","timestamp":1789052904415,"version":"build-2803163510"},"reference-count":265,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","award":["20A07"],"award-info":[{"award-number":["20A07"]}],"id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NIA","award":["R03NS112611"],"award-info":[{"award-number":["R03NS112611"]}]},{"name":"Fink Family Career Development Award in Neurology","award":["Fink Family Career Development Award in Neurology"],"award-info":[{"award-number":["Fink Family Career Development Award in Neurology"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Lewy body dementia (LBD) encompasses neurodegenerative dementias characterized by cognitive fluctuations, visual hallucinations, and parkinsonism. Clinical differentiation of LBD from Alzheimer\u2019s disease (AD) remains complex due to symptom overlap, yet approximately 25% of dementia cases are diagnosed as LBD postmortem, primarily identified by the presence of \u03b1-synuclein aggregates, tau tangles, and amyloid plaques. These pathological features position LBD as a comorbid condition of both Parkinson\u2019s disease (PD) and AD, with over 50% of LBD cases exhibiting co-pathologies. LBD\u2019s mixed pathology complicates the development of comprehensive models that reflect the full spectrum of LBD\u2019s etiological, clinical, and pathological features. While existing animal and cellular models have facilitated significant discoveries in PD and AD research, they lack specificity in capturing LBD\u2019s unique pathogenic mechanisms, limiting the exploration of therapeutic avenues for LBD specifically. This review assesses widely used PD and AD models in terms of their relevance to LBD, particularly focusing on their ability to replicate human disease pathology and assess treatment efficacy. Furthermore, we discuss potential modifications to these models to advance the understanding of LBD mechanisms and propose innovative research directions aimed at developing models with enhanced etiological, face, predictive, and construct validity.<\/jats:p>","DOI":"10.1186\/s13024-025-00837-w","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:57:35Z","timestamp":1745427455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Research models to study lewy body dementia"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7694-920X","authenticated-orcid":false,"given":"Suelen Lucio","family":"Boschen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarushi","family":"A. Mukerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"H. Faroqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"E. Rabichow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fryer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"1","key":"837_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nan.12648","volume":"47","author":"D Hansen","year":"2021","unstructured":"Hansen D, Ling H, Lashley T, Foley J, Strand C, Eid T, et al. Novel clinicopathological characteristics differentiate dementia with lewy bodies from Parkinson\u2019s disease dementia. Neuropathol Appl Neurobiol. 2021;47(1):143\u201356.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"837_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ncl.2017.01.004","volume":"35","author":"D Galasko","year":"2017","unstructured":"Galasko D. Lewy body disorders. Neurol Clin. 2017;35(2):325\u201338.","journal-title":"Neurol Clin"},{"issue":"21","key":"837_CR3","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between Abeta, Tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281\u20139.","journal-title":"J Neurosci"},{"issue":"5","key":"837_CR4","doi-asserted-by":"publisher","first-page":"27625","DOI":"10.4088\/JCP.AD19038BR1C","volume":"81","author":"D Aarsland","year":"2020","unstructured":"Aarsland D. Epidemiology and pathophysiology of dementia-related psychosis. J Clin Psychiatry. 2020;81(5):27625.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"837_CR5","doi-asserted-by":"publisher","first-page":"101441","DOI":"10.1016\/j.disamonth.2022.101441","volume":"69","author":"S Prasad","year":"2023","unstructured":"Prasad S, Katta MR, Abhishek S, Sridhar R, Valisekka SS, Hameed M, et al. Recent advances in lewy body dementia: A comprehensive review. Dis Mon. 2023;69(5):101441.","journal-title":"Dis Mon"},{"issue":"20","key":"837_CR6","doi-asserted-by":"publisher","first-page":"e2076","DOI":"10.1212\/WNL.0000000000009434","volume":"94","author":"DS Smirnov","year":"2020","unstructured":"Smirnov DS, Galasko D, Edland SD, Filoteo JV, Hansen LA, Salmon DP. Cognitive decline profiles differ in Parkinson disease dementia and dementia with lewy bodies. Neurology. 2020;94(20):e2076\u201387.","journal-title":"Neurology"},{"issue":"1","key":"837_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s42826-022-00128-1","volume":"38","author":"P Mukherjee","year":"2022","unstructured":"Mukherjee P, Roy S, Ghosh D, Nandi SK. Role of animal models in biomedical research: a review. Lab Anim Res. 2022;38(1):18.","journal-title":"Lab Anim Res"},{"issue":"4","key":"837_CR8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"837_CR9","volume-title":"Parkinson\u2019s disease: pathogenesis and clinical aspects","author":"JCBR Greenland","year":"2018","unstructured":"Greenland JCBR. The differential diagnosis of Parkinson\u2019s disease. In: Stoker TBGJ, editor. Parkinson\u2019s disease: pathogenesis and clinical aspects. Brisbane (AU): Codon; 2018."},{"key":"837_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.neubiorev.2016.07.010","volume":"68","author":"AA Moustafa","year":"2016","unstructured":"Moustafa AA, Chakravarthy S, Phillips JR, Gupta A, Keri S, Polner B, et al. Motor symptoms in Parkinson\u2019s disease: A unified framework. Neurosci Biobehavioral Reviews. 2016;68:727\u201340.","journal-title":"Neurosci Biobehavioral Reviews"},{"issue":"10423","key":"837_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson\u2019s disease. Lancet. 2024;403(10423):293\u2013304.","journal-title":"Lancet"},{"issue":"8","key":"837_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J, Tan EK. Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795\u2013808.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"837_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00018-022-04240-2","volume":"79","author":"GK Tofaris","year":"2022","unstructured":"Tofaris GK. Initiation and progression of \u03b1-synuclein pathology in Parkinson\u2019s disease. Cell Mol Life Sci. 2022;79(4):210.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"837_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41531-021-00273-9","volume":"8","author":"K Men\u0161\u00edkov\u00e1","year":"2022","unstructured":"Men\u0161\u00edkov\u00e1 K, Mat\u011bj R, Colosimo C, Rosales R, Tu\u010dkov\u00e1 L, Ehrmann J, et al. Lewy body disease or diseases with lewy bodies? Npj Parkinson\u2019s Disease. 2022;8(1):3.","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"1","key":"837_CR15","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Reviews Disease Primers. 2017;3(1):17013.","journal-title":"Nat Reviews Disease Primers"},{"issue":"10291","key":"837_CR16","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C. Parkinson\u2019s disease. Lancet. 2021;397(10291):2284\u2013303.","journal-title":"Lancet"},{"key":"837_CR17","doi-asserted-by":"crossref","unstructured":"Surguchov A. Invertebrate Models Untangle the Mechanism of Neurodegeneration in Parkinson\u2019s Disease. Cells. 2021;10(2).","DOI":"10.3390\/cells10020407"},{"key":"837_CR18","volume-title":"Parkinson\u2019s disease: pathogenesis and clinical aspects","author":"EASM Konnova","year":"2018","unstructured":"Konnova EASM. Animal models of Parkinson\u2019s disease. In: Stoker TBGJ, editor. Parkinson\u2019s disease: pathogenesis and clinical aspects. Brisbane (AU): Codon; 2018."},{"issue":"1","key":"837_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/npp.2009.131","volume":"35","author":"BW Balleine","year":"2010","unstructured":"Balleine BW, O\u2019Doherty JP. Human and rodent homologies in action control: corticostriatal determinants of Goal-Directed and habitual action. Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol. 2010;35(1):48\u201369.","journal-title":"Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol"},{"issue":"11","key":"837_CR20","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nrn2915","volume":"11","author":"P Redgrave","year":"2010","unstructured":"Redgrave P, Rodriguez M, Smith Y, Rodriguez-Oroz MC, Lehericy S, Bergman H, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson\u2019s disease. Nat Rev Neurosci. 2010;11(11):760\u201372.","journal-title":"Nat Rev Neurosci"},{"key":"837_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fnbeh.2013.00175","volume":"7","author":"FL Campos","year":"2013","unstructured":"Campos FL, Carvalho MM, Cristov\u00e3o AC, Je G, Baltazar G, Salgado AJ, et al. Rodent models of Parkinson\u2019s disease: beyond the motor symptomatology. Front Behav Neurosci. 2013;7:175.","journal-title":"Front Behav Neurosci"},{"key":"837_CR22","doi-asserted-by":"crossref","unstructured":"Zhang TD, Kolbe SC, Beauchamp LC, Woodbridge EK, Finkelstein DI, Burrows EL. How Well Do Rodent Models of Parkinson\u2019s Disease Recapitulate Early Non-Motor Phenotypes? A Systematic Review. Biomedicines. 2022;10(12).","DOI":"10.3390\/biomedicines10123026"},{"issue":"6","key":"837_CR23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/mds.27337","volume":"33","author":"MA Cenci","year":"2018","unstructured":"Cenci MA, Crossman AR. Animal models of l-dopa-induced dyskinesia in Parkinson\u2019s disease. Mov Disord. 2018;33(6):889\u201399.","journal-title":"Mov Disord"},{"key":"837_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/7854_2014_352","volume":"22","author":"TM Johnston","year":"2015","unstructured":"Johnston TM, Fox SH. Symptomatic models of Parkinson\u2019s disease and L-DOPA-Induced dyskinesia in Non-human Primates. Curr Top Behav Neurosci. 2015;22:221\u201335.","journal-title":"Curr Top Behav Neurosci"},{"issue":"3","key":"837_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/ejn.14173","volume":"49","author":"SH Fox","year":"2019","unstructured":"Fox SH, Brotchie JM, Viewpoint. Developing drugs for levodopa-induced dyskinesia in PD: lessons learnt, what does the future hold? Eur J Neurosci. 2019;49(3):399\u2013409.","journal-title":"Eur J Neurosci"},{"key":"837_CR26","doi-asserted-by":"crossref","unstructured":"Khan E, Hasan I, Haque ME. Parkinson\u2019s Disease: Exploring Different Animal Model Systems. Int J Mol Sci. 2023;24(10).","DOI":"10.3390\/ijms24109088"},{"issue":"1","key":"837_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0006-8993(72)90248-X","volume":"47","author":"J Hedreen","year":"1972","unstructured":"Hedreen J, Chalmers J. Neuronal degeneration in rat brain induced by 6-hydroxydopamine; a histological and biochemical study. Brain Res. 1972;47(1):1\u201336.","journal-title":"Brain Res"},{"issue":"2","key":"837_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0006-8993(76)90877-5","volume":"102","author":"F Javoy","year":"1976","unstructured":"Javoy F, Sotelo C, Herbet A, Agid Y. Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system. Brain Res. 1976;102(2):201\u201315.","journal-title":"Brain Res"},{"issue":"6","key":"837_CR29","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3390\/biomedicines9060598","volume":"9","author":"D Masini","year":"2021","unstructured":"Masini D, Plewnia C, Bertho M, Scalbert N, Caggiano V, Fisone G. A guide to the generation of a 6-Hydroxydopamine mouse model of Parkinson\u2019s disease for the study of Non-Motor symptoms. Biomedicines. 2021;9(6):598.","journal-title":"Biomedicines"},{"key":"837_CR30","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/B978-0-12-815950-7.00040-0","volume-title":"Genetics, neurology, behavior, and diet in Parkinson\u2019","author":"K Kaczy\u0144ska","year":"2020","unstructured":"Kaczy\u0144ska K, Andrzejewski K. Chapter 40\u20136-hydroxydopamine-induced model of Parkinson\u2019s disease. In: Martin CR, Preedy VR, editors. Genetics, neurology, behavior, and diet in Parkinson\u2019. s Disease: Academic; 2020. pp. 627\u201342."},{"issue":"3","key":"837_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.21307\/ane-2017-020","volume":"76","author":"MS Nielsen","year":"2016","unstructured":"Nielsen MS, Glud AN, M\u00f8ller A, Mogensen P, Bender D, S\u00f8rensen JC, et al. Continuous MPTP intoxication in the G\u00f6ttingen minipig results in chronic parkinsonian deficits. Acta Neurobiol Exp (Wars). 2016;76(3):199\u2013211.","journal-title":"Acta Neurobiol Exp (Wars)"},{"issue":"1","key":"837_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3233\/JPD-2011-11023","volume":"1","author":"GE Meredith","year":"2011","unstructured":"Meredith GE, Rademacher DJ. MPTP mouse models of Parkinson\u2019s disease: an update. J Parkinsons Dis. 2011;1(1):19\u201333.","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"837_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S0022-3565(24)39240-7","volume":"293","author":"RG Staal","year":"2000","unstructured":"Staal RG, Sonsalla PK. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J Pharmacol Exp Ther. 2000;293(2):336\u201342.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"837_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jneumeth.2005.04.005","volume":"148","author":"MM Ferro","year":"2005","unstructured":"Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci MEM, Canteras NS, Da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson\u2019s disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods. 2005;148(1):78\u201387.","journal-title":"J Neurosci Methods"},{"issue":"1","key":"837_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0165-0270(99)00184-3","volume":"96","author":"C Imbert","year":"2000","unstructured":"Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the macaque monkey. J Neurosci Methods. 2000;96(1):71\u20136.","journal-title":"J Neurosci Methods"},{"issue":"8","key":"837_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/35086062","volume":"2","author":"E Bezard","year":"2001","unstructured":"Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2(8):577\u201388.","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"837_CR37","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/j.1460-9568.2004.03586.x","volume":"20","author":"E Decamp","year":"2004","unstructured":"Decamp E, Schneider J. Attention and executive function deficits in chronic low-dose MPTP\u2010treated non\u2010human primates. Eur J Neurosci. 2004;20(5):1371\u20138.","journal-title":"Eur J Neurosci"},{"issue":"3","key":"837_CR38","doi-asserted-by":"publisher","first-page":"a009308","DOI":"10.1101\/cshperspect.a009308","volume":"2","author":"G Porras","year":"2012","unstructured":"Porras G, Li Q, Bezard E. Modeling Parkinson\u2019s disease in primates: the MPTP model. Cold Spring Harb Perspect Med. 2012;2(3):a009308.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"837_CR39","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2174\/1570159X21666230216101659","volume":"21","author":"CC Real","year":"2023","unstructured":"Real CC, Binda KH, Thomsen MB, Lillethorup TP, Brooks DJ, Landau AM. Selecting the best animal model of Parkinson\u2019s disease for your research purpose: insight from in vivo PET imaging studies. Curr Neuropharmacol. 2023;21(5):1241\u201372.","journal-title":"Curr Neuropharmacol"},{"issue":"5","key":"837_CR40","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1021\/acs.chemrestox.0c00522","volume":"34","author":"J Innos","year":"2021","unstructured":"Innos J, Hickey MA. Using rotenone to model Parkinson\u2019s disease in mice: A review of the role of pharmacokinetics. Chem Res Toxicol. 2021;34(5):1223\u201339.","journal-title":"Chem Res Toxicol"},{"key":"837_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuro.2016.11.006","volume":"58","author":"Y Wang","year":"2017","unstructured":"Wang Y, Liu W, Yang J, Wang F, Sima Y, Zhong Z-m, et al. Parkinson\u2019s disease-like motor and non-motor symptoms in rotenone-treated zebrafish. Neurotoxicology. 2017;58:103\u20139.","journal-title":"Neurotoxicology"},{"key":"837_CR42","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.neuroscience.2013.04.037","volume":"246","author":"R St. Laurent","year":"2013","unstructured":"St. Laurent R, O\u2019Brien LM, Ahmad ST. Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson\u2019s disease. Neuroscience. 2013;246:382\u201390.","journal-title":"Neuroscience"},{"issue":"1","key":"837_CR43","doi-asserted-by":"publisher","first-page":"45465","DOI":"10.1038\/srep45465","volume":"7","author":"S Heinz","year":"2017","unstructured":"Heinz S, Freyberger A, Lawrenz B, Schladt L, Schmuck G, Ellinger-Ziegelbauer H. Mechanistic investigations of the mitochondrial complex I inhibitor rotenone in the context of Pharmacological and safety evaluation. Sci Rep. 2017;7(1):45465.","journal-title":"Sci Rep"},{"issue":"1","key":"837_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41531-023-00561-6","volume":"9","author":"AD Van Laar","year":"2023","unstructured":"Van Laar AD, Webb KR, Keeney MT, Van Laar VS, Zharikov A, Burton EA, et al. Transient exposure to rotenone causes degeneration and progressive parkinsonian motor deficits, neuroinflammation, and synucleinopathy. Npj Parkinson\u2019s Disease. 2023;9(1):121.","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"6","key":"837_CR45","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.pnpbp.2010.06.004","volume":"34","author":"RM Santiago","year":"2010","unstructured":"Santiago RM, Barbieiro J, Lima MM, Dombrowski PA, Andreatini R, Vital MA. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson\u2019s disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):1104\u201314.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"837_CR46","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1111\/nmo.12070","volume":"25","author":"M Tasselli","year":"2013","unstructured":"Tasselli M, Chaumette T, Paillusson S, Monnet Y, Lafoux A, Huchet-Cadiou C, et al. Effects of oral administration of rotenone on Gastrointestinal functions in mice. Neurogastroenterology Motil. 2013;25(3):e183\u201393.","journal-title":"Neurogastroenterology Motil"},{"issue":"8","key":"837_CR47","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/FBP.0000000000000699","volume":"33","author":"JK Barbiero","year":"2022","unstructured":"Barbiero JK, Ramos DC, Boschen S, Bassani T, Da Cunha C, Vital MABF. Fenofibrate promotes neuroprotection in a model of rotenone-induced Parkinson\u2019s disease. Behav Pharmacol. 2022;33(8):513\u201326.","journal-title":"Behav Pharmacol"},{"issue":"1","key":"837_CR48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1248\/bpb.34.92","volume":"34","author":"M Inden","year":"2011","unstructured":"Inden M, Kitamura Y, Abe M, Tamaki A, Takata K, Taniguchi T. Parkinsonian rotenone mouse model: Reevaluation of long-term administration of rotenone in C57BL\/6 mice. Biol Pharm Bull. 2011;34(1):92\u20136.","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"837_CR49","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","volume":"34","author":"BI Giasson","year":"2002","unstructured":"Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VMY. Neuronal \u03b1-Synucleinopathy with severe movement disorder in mice expressing A53T human \u03b1-Synuclein. Neuron. 2002;34(4):521\u201333.","journal-title":"Neuron"},{"issue":"19","key":"837_CR50","doi-asserted-by":"publisher","first-page":"6652","DOI":"10.1074\/jbc.RA119.012179","volume":"295","author":"SA Morgan","year":"2020","unstructured":"Morgan SA, Lavenir I, Fan J, Masuda-Suzukake M, Passarella D, DeTure MA, et al. \u03b1-Synuclein filaments from Transgenic mouse and human synucleinopathy-containing brains are major seed-competent species. J Biol Chem. 2020;295(19):6652\u201364.","journal-title":"J Biol Chem"},{"issue":"1","key":"837_CR51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/brain\/awz380","volume":"143","author":"T Taguchi","year":"2019","unstructured":"Taguchi T, Ikuno M, Hondo M, Parajuli LK, Taguchi K, Ueda J, et al. \u03b1-Synuclein BAC Transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson\u2019s disease model. Brain. 2019;143(1):249\u201365.","journal-title":"Brain"},{"key":"837_CR52","doi-asserted-by":"publisher","first-page":"726476","DOI":"10.3389\/fnins.2021.726476","volume":"15","author":"L Veys","year":"2021","unstructured":"Veys L, Devroye J, Lefevere E, Cools L, Vandenabeele M, De Groef L. Characterizing the retinal phenotype of the Thy1-h [A30P] \u03b1-syn mouse model of Parkinson\u2019s disease. Front NeuroSci. 2021;15:726476.","journal-title":"Front NeuroSci"},{"issue":"5","key":"837_CR53","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/jnr.10231","volume":"68","author":"E Rockenstein","year":"2002","unstructured":"Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, et al. Differential neuropathological alterations in Transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002;68(5):568\u201378.","journal-title":"J Neurosci Res"},{"issue":"2","key":"837_CR54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","volume":"9","author":"MF Chesselet","year":"2012","unstructured":"Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR. A progressive mouse model of Parkinson\u2019s disease: the Thy1-aSyn (Line 61) mice. Neurotherapeutics. 2012;9(2):297\u2013314.","journal-title":"Neurotherapeutics"},{"key":"837_CR55","doi-asserted-by":"crossref","unstructured":"Cenci MA, Bj\u00f6rklund A. Chapter 2 - Animal models for preclinical Parkinson\u2019s research: An update and critical appraisal. In: Bj\u00f6rklund A, Cenci MA, editors. Progress in brain research. Volume 252. Elsevier; 2020. pp. 27\u201359.","DOI":"10.1016\/bs.pbr.2020.02.003"},{"issue":"7","key":"837_CR56","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.3390\/ijms21072464","volume":"21","author":"SJ Chia","year":"2020","unstructured":"Chia SJ, Tan E-K, Chao Y-X. Historical perspective: models of Parkinson\u2019s disease. Int J Mol Sci. 2020;21(7):2464.","journal-title":"Int J Mol Sci"},{"key":"837_CR57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.nbd.2013.10.005","volume":"62","author":"TN Taylor","year":"2014","unstructured":"Taylor TN, Potgieter D, Anwar S, Senior SL, Janezic S, Threlfell S, et al. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P \u03b1-synuclein BAC Transgenic mouse. Neurobiol Dis. 2014;62:193\u2013207.","journal-title":"Neurobiol Dis"},{"issue":"42","key":"837_CR58","doi-asserted-by":"publisher","first-page":"E4016","DOI":"10.1073\/pnas.1309143110","volume":"110","author":"S Janezic","year":"2013","unstructured":"Janezic S, Threlfell S, Dodson PD, Dowie MJ, Taylor TN, Potgieter D, et al. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci USA. 2013;110(42):E4016\u201325.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"837_CR59","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13311-021-01169-5","volume":"19","author":"S Okuda","year":"2022","unstructured":"Okuda S, Uemura N, Sawamura M, Taguchi T, Ikuno M, Uemura MT, et al. Rapid induction of dopaminergic neuron loss accompanied by lewy Body-Like inclusions in A53T BAC-SNCA Transgenic mice. Neurotherapeutics. 2022;19(1):289\u2013304.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"837_CR60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.neures.2012.03.010","volume":"73","author":"H Yamakado","year":"2012","unstructured":"Yamakado H, Moriwaki Y, Yamasaki N, Miyakawa T, Kurisu J, Uemura K, et al. \u03b1-Synuclein BAC Transgenic mice as a model for Parkinson\u2019s disease manifested decreased anxiety-like behavior and hyperlocomotion. Neurosci Res. 2012;73(2):173\u20137.","journal-title":"Neurosci Res"},{"issue":"9","key":"837_CR61","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jnr.24014","volume":"95","author":"T Kikuchi","year":"2017","unstructured":"Kikuchi T, Morizane A, Doi D, Okita K, Nakagawa M, Yamakado H, et al. Idiopathic Parkinson\u2019s disease patient-derived induced pluripotent stem cells function as midbrain dopaminergic neurons in rodent brains. J Neurosci Res. 2017;95(9):1829\u201337.","journal-title":"J Neurosci Res"},{"issue":"7","key":"837_CR62","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1523\/JNEUROSCI.22-07-02780.2002","volume":"22","author":"D Kirik","year":"2002","unstructured":"Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, et al. Parkinson-like neurodegeneration induced by targeted overexpression of \u03b1-synuclein in the nigrostriatal system. J Neurosci. 2002;22(7):2780\u201391.","journal-title":"J Neurosci"},{"issue":"3","key":"837_CR63","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.nbd.2011.12.013","volume":"45","author":"M Decressac","year":"2012","unstructured":"Decressac M, Mattsson B, Lundblad M, Weikop P, Bj\u00f6rklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of \u03b1-synuclein in midbrain dopamine neurons. Neurobiol Dis. 2012;45(3):939\u201353.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"837_CR64","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1038\/s41598-017-06724-9","volume":"7","author":"J-A Phan","year":"2017","unstructured":"Phan J-A, Stokholm K, Zareba-Paslawska J, Jakobsen S, Vang K, Gjedde A, et al. Early synaptic dysfunction induced by \u03b1-synuclein in a rat model of Parkinson\u2019s disease. Sci Rep. 2017;7(1):6363.","journal-title":"Sci Rep"},{"issue":"11","key":"837_CR65","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1016\/j.neurobiolaging.2014.04.032","volume":"35","author":"M Oliveras-Salv\u00e1","year":"2014","unstructured":"Oliveras-Salv\u00e1 M, Macchi F, Coessens V, Deleersnijder A, G\u00e9rard M, Van der Perren A, et al. Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice. Neurobiol Aging. 2014;35(11):2625\u201336.","journal-title":"Neurobiol Aging"},{"key":"837_CR66","doi-asserted-by":"crossref","unstructured":"Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bj\u00f6rklund A. Nigrostriatal \u03b1-synucleinopathy induced by viral vector-mediated overexpression of human \u03b1-synuclein: A new primate model of Parkinson\u2019s disease. Proceedings of the National Academy of Sciences. 2003;100(5):2884-9.","DOI":"10.1073\/pnas.0536383100"},{"issue":"6","key":"837_CR67","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/j.1471-4159.2006.04310.x","volume":"100","author":"JL St Martin","year":"2007","unstructured":"St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, et al. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia Nigra. J Neurochem. 2007;100(6):1449\u201357.","journal-title":"J Neurochem"},{"issue":"1","key":"837_CR68","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"J-H Wang","year":"2024","unstructured":"Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Therapy. 2024;9(1):78.","journal-title":"Signal Transduct Target Therapy"},{"issue":"9","key":"837_CR69","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/nprot.2014.143","volume":"9","author":"LA Volpicelli-Daley","year":"2014","unstructured":"Volpicelli-Daley LA, Luk KC, Lee VM. Addition of exogenous \u03b1-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous \u03b1-synuclein to lewy body and lewy neurite-like aggregates. Nat Protoc. 2014;9(9):2135\u201346.","journal-title":"Nat Protoc"},{"issue":"2","key":"837_CR70","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JPD-171248","volume":"8","author":"NK Polinski","year":"2018","unstructured":"Polinski NK, Volpicelli-Daley LA, Sortwell CE, Luk KC, Cremades N, Gottler LM, et al. Best practices for generating and using Alpha-Synuclein Pre-Formed fibrils to model Parkinson\u2019s disease in rodents. J Parkinsons Dis. 2018;8(2):303\u201322.","journal-title":"J Parkinsons Dis"},{"key":"837_CR71","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.nbd.2017.05.014","volume":"105","author":"H Abdelmotilib","year":"2017","unstructured":"Abdelmotilib H, Maltbie T, Delic V, Liu Z, Hu X, Fraser KB, et al. \u03b1-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic neurodegeneration. Neurobiol Dis. 2017;105:84\u201398.","journal-title":"Neurobiol Dis"},{"issue":"6109","key":"837_CR72","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm V, Carroll J, Zhang B, O\u2019Brien P, Trojanowski JQ, et al. Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949\u201353.","journal-title":"Science"},{"key":"837_CR73","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.nbd.2015.06.003","volume":"82","author":"KL Paumier","year":"2015","unstructured":"Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ, et al. Intrastriatal injection of pre-formed mouse \u03b1-synuclein fibrils into rats triggers \u03b1-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol Dis. 2015;82:185\u201399.","journal-title":"Neurobiol Dis"},{"key":"837_CR74","doi-asserted-by":"crossref","unstructured":"Patterson JR, Polinski NK, Duffy MF, Kemp CJ, Luk KC, Volpicelli-Daley LA et al. Generation of Alpha-Synuclein preformed fibrils from monomers and use in vivo. J Vis Exp. 2019(148).","DOI":"10.3791\/59758-v"},{"key":"837_CR75","doi-asserted-by":"crossref","unstructured":"Verma DK, Seo BA, Ghosh A, Ma SX, Hernandez-Quijada K, Andersen JK et al. Alpha-Synuclein Preformed Fibrils Induce Cellular Senescence in Parkinson\u2019s Disease Models. Cells. 2021;10(7).","DOI":"10.3390\/cells10071694"},{"key":"837_CR76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.parkreldis.2021.06.010","volume":"89","author":"JW Howe","year":"2021","unstructured":"Howe JW, Sortwell CE, Duffy MF, Kemp CJ, Russell CP, Kubik M, et al. Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein. Parkinsonism Relat Disord. 2021;89:41\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"837_CR77","doi-asserted-by":"publisher","first-page":"105804","DOI":"10.1016\/j.nbd.2022.105804","volume":"171","author":"AC Stoll","year":"2022","unstructured":"Stoll AC, Sortwell CE. Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity. Neurobiol Dis. 2022;171:105804.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"837_CR78","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1038\/s41467-023-42705-5","volume":"14","author":"N Uemura","year":"2023","unstructured":"Uemura N, Marotta NP, Ara J, Meymand ES, Zhang B, Kameda H, et al. \u03b1-Synuclein aggregates amplified from patient-derived lewy bodies recapitulate lewy body diseases in mice. Nat Commun. 2023;14(1):6892.","journal-title":"Nat Commun"},{"key":"837_CR79","doi-asserted-by":"crossref","unstructured":"Slanzi A, Iannoto G, Rossi B, Zenaro E, Constantin G. In Vitro models of neurodegenerative diseases. Front Cell Dev Biology. 2020;8.","DOI":"10.3389\/fcell.2020.00328"},{"key":"837_CR80","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.brainres.2010.03.102","volume":"1337","author":"FM Lopes","year":"2010","unstructured":"Lopes FM, Schr\u00f6der R, da Frota J\u00fanior MLC, Zanotto-Filho A, M\u00fcller CB, Pires AS, et al. Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Res. 2010;1337:85\u201394.","journal-title":"Brain Res"},{"issue":"1","key":"837_CR81","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1038\/s41598-024-55516-5","volume":"14","author":"ZB Kaya","year":"2024","unstructured":"Kaya ZB, Santiago-Padilla V, Lim M, Boschen SL, Atilla P, McLean PJ. Optimizing SH-SY5Y cell culture: exploring the beneficial effects of an alternative media supplement on cell proliferation and viability. Sci Rep. 2024;14(1):4775.","journal-title":"Sci Rep"},{"key":"837_CR82","doi-asserted-by":"crossref","unstructured":"Taylor-Whiteley TR, Le Maitre CL, Duce JA, Dalton CF, Smith DP. Recapitulating Parkinson\u2019s disease pathology in a three-dimensional human neural cell culture model. Dis Models Mech. 2019;12(4).","DOI":"10.1242\/dmm.038042"},{"issue":"1","key":"837_CR83","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-017-0149-0","volume":"12","author":"H Xicoy","year":"2017","unstructured":"Xicoy H, Wieringa B, Martens GJ. The SH-SY5Y cell line in Parkinson\u2019s disease research: a systematic review. Mol Neurodegener. 2017;12(1):10.","journal-title":"Mol Neurodegener"},{"issue":"41","key":"837_CR84","doi-asserted-by":"publisher","first-page":"38884","DOI":"10.1074\/jbc.M205518200","volume":"277","author":"J Lotharius","year":"2002","unstructured":"Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P. Effect of mutant \u03b1-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem. 2002;277(41):38884\u201394.","journal-title":"J Biol Chem"},{"issue":"5","key":"837_CR85","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/j.1471-4159.2011.07255.x","volume":"119","author":"D Scholz","year":"2011","unstructured":"Scholz D, P\u00f6ltl D, Genewsky A, Weng M, Waldmann T, Schildknecht S, et al. Rapid, complete and large-scale generation of post\u2010mitotic neurons from the human LUHMES cell line. J Neurochem. 2011;119(5):957\u201371.","journal-title":"J Neurochem"},{"issue":"1","key":"837_CR86","doi-asserted-by":"publisher","first-page":"e3881","DOI":"10.21769\/BioProtoc.3881","volume":"11","author":"T Leah","year":"2021","unstructured":"Leah T, Vazquez-Villase\u00f1or I, Ferraiuolo L, Wharton SB, Mortiboys H. A Parkinson\u2019s Disease-relevant mitochondrial and neuronal morphology High-throughput screening assay in LUHMES cells. Bio Protoc. 2021;11(1):e3881.","journal-title":"Bio Protoc"},{"issue":"1","key":"837_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuro.2007.09.007","volume":"29","author":"E Van Vliet","year":"2008","unstructured":"Van Vliet E, Morath S, Eskes C, Linge J, Rappsilber J, Honegger P, et al. A novel in vitro metabolomics approach for neurotoxicity testing, proof of principle for Methyl mercury chloride and caffeine. Neurotoxicology. 2008;29(1):1\u201312.","journal-title":"Neurotoxicology"},{"issue":"11","key":"837_CR88","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1007\/s00204-015-1637-z","volume":"90","author":"L Smirnova","year":"2016","unstructured":"Smirnova L, Harris G, Delp J, Valadares M, Pamies D, Hogberg HT, et al. A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis. Arch Toxicol. 2016;90(11):2725\u201343.","journal-title":"Arch Toxicol"},{"issue":"18","key":"837_CR89","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1093\/hmg\/9.18.2683","volume":"9","author":"SJ Tabrizi","year":"2000","unstructured":"Tabrizi SJ, Orth M, Wilkinson JM, Taanman J-W, Warner TT, Cooper JM, et al. Expression of mutant \u03b1-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet. 2000;9(18):2683\u20139.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"837_CR90","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0306-4522(01)00113-0","volume":"104","author":"P McLean","year":"2001","unstructured":"McLean P, Kawamata H, Hyman B. \u03b1-Synuclein\u2013enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience. 2001;104(3):901\u201312.","journal-title":"Neuroscience"},{"issue":"4","key":"837_CR91","doi-asserted-by":"publisher","first-page":"e1867","DOI":"10.1371\/journal.pone.0001867","volume":"3","author":"TF Outeiro","year":"2008","unstructured":"Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, et al. Formation of toxic oligomeric \u03b1-synuclein species in living cells. PLoS ONE. 2008;3(4):e1867.","journal-title":"PLoS ONE"},{"issue":"11","key":"837_CR92","doi-asserted-by":"publisher","first-page":"e1004741","DOI":"10.1371\/journal.pgen.1004741","volume":"10","author":"DF L\u00e1zaro","year":"2014","unstructured":"L\u00e1zaro DF, Rodrigues EF, Langohr R, Shahpasandzadeh H, Ribeiro T, Guerreiro P, et al. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet. 2014;10(11):e1004741.","journal-title":"PLoS Genet"},{"issue":"2","key":"837_CR93","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1471-4159.2008.05407.x","volume":"106","author":"F Opazo","year":"2008","unstructured":"Opazo F, Krenz A, Heermann S, Schulz JB, Falkenburger BH. Accumulation and clearance of \u03b1-synuclein aggregates demonstrated by time\u2010lapse imaging. J Neurochem. 2008;106(2):529\u201340.","journal-title":"J Neurochem"},{"issue":"12","key":"837_CR94","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1096\/fj.05-5422com","volume":"20","author":"J Klucken","year":"2006","unstructured":"Klucken J, Outeiro TF, Nguyen P, McLean PJ, Hyman BT. Detection of novel intracellular O-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J. 2006;20(12):2050\u20137.","journal-title":"FASEB J"},{"issue":"38","key":"837_CR95","doi-asserted-by":"publisher","first-page":"E5308","DOI":"10.1073\/pnas.1514475112","volume":"112","author":"SB Prusiner","year":"2015","unstructured":"Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, et al. Evidence for \u03b1-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci. 2015;112(38):E5308\u201317.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"837_CR96","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/jnc.14806","volume":"150","author":"M Delenclos","year":"2019","unstructured":"Delenclos M, Burgess JD, Lamprokostopoulou A, Outeiro TF, Vekrellis K, McLean PJ. Cellular models of alpha-synuclein toxicity and aggregation. J Neurochem. 2019;150(5):566\u201376.","journal-title":"J Neurochem"},{"issue":"10","key":"837_CR97","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812\u20138.","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"837_CR98","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","volume":"20","author":"A Iranzo","year":"2021","unstructured":"Iranzo A, Fairfoul G, Ayudhaya ACN, Serradell M, Gelpi E, Vilaseca I, et al. Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 2021;20(3):203\u201312.","journal-title":"Lancet Neurol"},{"issue":"2","key":"837_CR99","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C, et al. Development of a biochemical diagnosis of Parkinson disease by detection of \u03b1-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 2017;74(2):163\u201372.","journal-title":"JAMA Neurol"},{"key":"837_CR100","first-page":"3916","volume":"55","author":"K Sano","year":"2018","unstructured":"Sano K, Atarashi R, Satoh K, Ishibashi D, Nakagaki T, Iwasaki Y, et al. Prion-like seeding of misfolded \u03b1-synuclein in the brains of dementia with lewy body patients in RT-QUIC. Mol Neurobiol. 2018;55:3916\u201330.","journal-title":"Mol Neurobiol"},{"key":"837_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-018-0508-2","volume":"6","author":"BR Groveman","year":"2018","unstructured":"Groveman BR, Orr\u00f9 CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B, et al. Rapid and ultra-sensitive quantitation of disease-associated \u03b1-synuclein seeds in brain and cerebrospinal fluid by \u0391Syn RT-QuIC. Acta Neuropathol Commun. 2018;6:1\u201310.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"837_CR102","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaneurol.2020.3311","volume":"78","author":"Z Wang","year":"2021","unstructured":"Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M, et al. Skin \u03b1-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol. 2021;78(1):30\u201340.","journal-title":"JAMA Neurol"},{"issue":"1","key":"837_CR103","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41531-021-00242-2","volume":"7","author":"A Kuzkina","year":"2021","unstructured":"Kuzkina A, Bargar C, Schmitt D, R\u00f6\u00dfle J, Wang W, Schubert AL, et al. Diagnostic value of skin RT-QuIC in Parkinson\u2019s disease: a two-laboratory study. NPJ Parkinsons Dis. 2021;7(1):99.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"837_CR104","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","volume":"9","author":"C Bargar","year":"2021","unstructured":"Bargar C, Wang W, Gunzler SA, LeFevre A, Wang Z, Lerner AJ, et al. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson\u2019s disease and dementia with lewy bodies. Acta Neuropathol Commun. 2021;9(1):62.","journal-title":"Acta Neuropathol Commun"},{"key":"837_CR105","doi-asserted-by":"crossref","unstructured":"Dong TT, Satoh K. The latest research on RT-QuIC Assays-A literature review. Pathogens. 2021;10(3).","DOI":"10.3390\/pathogens10030305"},{"key":"837_CR106","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jnc.13618","volume":"139","author":"BH Falkenburger","year":"2016","unstructured":"Falkenburger BH, Saridaki T, Dinter E. Cellular models for Parkinson\u2019s disease. J Neurochem. 2016;139:121\u201330.","journal-title":"J Neurochem"},{"issue":"4","key":"837_CR107","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ana.23747","volume":"72","author":"EC Freundt","year":"2012","unstructured":"Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, et al. Neuron-to-neuron transmission of \u03b1-synuclein fibrils through axonal transport. Ann Neurol. 2012;72(4):517\u201324.","journal-title":"Ann Neurol"},{"issue":"4","key":"837_CR108","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41419-018-0468-2","volume":"9","author":"Y Che","year":"2018","unstructured":"Che Y, Hou L, Sun F, Zhang C, Liu X, Piao F, et al. Taurine protects dopaminergic neurons in a mouse Parkinson\u2019s disease model through Inhibition of microglial M1 polarization. Cell Death Dis. 2018;9(4):435.","journal-title":"Cell Death Dis"},{"key":"837_CR109","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fncel.2018.00247","volume":"12","author":"SA Ferreira","year":"2018","unstructured":"Ferreira SA, Romero-Ramos M. Microglia response during Parkinson\u2019s disease: Alpha-Synuclein intervention. Front Cell Neurosci. 2018;12:247.","journal-title":"Front Cell Neurosci"},{"issue":"Suppl 1","key":"837_CR110","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jnc.13618","volume":"139","author":"BH Falkenburger","year":"2016","unstructured":"Falkenburger BH, Saridaki T, Dinter E. Cellular models for Parkinson\u2019s disease. J Neurochem. 2016;139(Suppl 1):121\u201330.","journal-title":"J Neurochem"},{"issue":"4","key":"837_CR111","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3233\/JPD-181353","volume":"8","author":"H Li","year":"2018","unstructured":"Li H, Jiang H, Zhang B, Feng J. Modeling Parkinson\u2019s disease using Patient-specific induced pluripotent stem cells. J Parkinson\u2019s Disease. 2018;8(4):479\u201393.","journal-title":"J Parkinson\u2019s Disease"},{"key":"837_CR112","doi-asserted-by":"crossref","unstructured":"Avazzadeh S, Baena JM, Keighron C, Feller-Sanchez Y, Quinlan LR. Modelling Parkinson\u2019s Disease: iPSCs towards Better Understanding of Human Pathology. Brain Sci. 2021;11(3).","DOI":"10.3390\/brainsci11030373"},{"issue":"1","key":"837_CR113","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1038\/s41467-020-17165-w","volume":"11","author":"D Doi","year":"2020","unstructured":"Doi D, Magotani H, Kikuchi T, Ikeda M, Hiramatsu S, Yoshida K, et al. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson\u2019s disease. Nat Commun. 2020;11(1):3369.","journal-title":"Nat Commun"},{"issue":"20","key":"837_CR114","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","volume":"382","author":"JS Schweitzer","year":"2020","unstructured":"Schweitzer JS, Song B, Herrington TM, Park T-Y, Lee N, Ko S, et al. Personalized iPSC-Derived dopamine progenitor cells for Parkinson\u2019s disease. N Engl J Med. 2020;382(20):1926\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"837_CR115","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/ncomms1453","volume":"2","author":"MJ Devine","year":"2011","unstructured":"Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, et al. Parkinson\u2019s disease induced pluripotent stem cells with triplication of the \u03b1-synuclein locus. Nat Commun. 2011;2(1):440.","journal-title":"Nat Commun"},{"issue":"10","key":"837_CR116","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.celrep.2018.05.009","volume":"23","author":"DC Sch\u00f6ndorf","year":"2018","unstructured":"Sch\u00f6ndorf DC, Ivanyuk D, Baden P, Sanchez-Martinez A, De Cicco S, Yu C, et al. The NAD\u2009+\u2009Precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson\u2019s disease. Cell Rep. 2018;23(10):2976\u201388.","journal-title":"Cell Rep"},{"issue":"1","key":"837_CR117","doi-asserted-by":"publisher","first-page":"9033","DOI":"10.1038\/s41598-018-27058-0","volume":"8","author":"D Little","year":"2018","unstructured":"Little D, Luft C, Mosaku O, Lorvellec M, Yao Z, Paillusson S, et al. A single cell high content assay detects mitochondrial dysfunction in iPSC-derived neurons with mutations in SNCA. Sci Rep. 2018;8(1):9033.","journal-title":"Sci Rep"},{"key":"837_CR118","doi-asserted-by":"publisher","first-page":"104581","DOI":"10.1016\/j.nbd.2019.104581","volume":"132","author":"H Bogetofte","year":"2019","unstructured":"Bogetofte H, Jensen P, Okarmus J, Schmidt SI, Agger M, Ryding M, et al. Perturbations in RhoA signalling cause altered migration and impaired neuritogenesis in human iPSC-derived neural cells with PARK2 mutation. Neurobiol Dis. 2019;132:104581.","journal-title":"Neurobiol Dis"},{"key":"837_CR119","doi-asserted-by":"publisher","first-page":"e32866","DOI":"10.7554\/eLife.32866","volume":"7","author":"G-L McLelland","year":"2018","unstructured":"McLelland G-L, Goiran T, Yi W, Dorval G, Chen CX, Lauinger ND, et al. Mfn2 ubiquitination by PINK1\/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy. eLife. 2018;7:e32866.","journal-title":"eLife"},{"issue":"6","key":"837_CR120","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.stem.2016.08.002","volume":"19","author":"C-H Hsieh","year":"2016","unstructured":"Hsieh C-H, Shaltouki A, Gonzalez AE, da Cruz AB, Burbulla LF, Lawrence ES, et al. Functional impairment in Miro degradation and mitophagy is a shared feature in Familial and sporadic Parkinson\u2019s disease. Cell Stem Cell. 2016;19(6):709\u201324.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"837_CR121","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/emmm.201200215","volume":"4","author":"A S\u00e1nchez-Dan\u00e9s","year":"2012","unstructured":"S\u00e1nchez-Dan\u00e9s A, Richaud-Patin Y, Carballo-Carbajal I, Jim\u00e9nez-Delgado S, Caig C, Mora S, et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson\u2019s disease. EMBO Mol Med. 2012;4(5):380\u201395.","journal-title":"EMBO Mol Med"},{"issue":"6357","key":"837_CR122","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1126\/science.aam9080","volume":"357","author":"LF Burbulla","year":"2017","unstructured":"Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson\u2019s disease. Science. 2017;357(6357):1255\u201361.","journal-title":"Science"},{"issue":"12","key":"837_CR123","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.15252\/emmm.201505439","volume":"7","author":"R Fern\u00e1ndez-Santiago","year":"2015","unstructured":"Fern\u00e1ndez-Santiago R, Carballo-Carbajal I, Castellano G, Torrent R, Richaud Y, S\u00e1nchez-Dan\u00e9s A, et al. Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson\u2019s disease patients. EMBO Mol Med. 2015;7(12):1529\u201346.","journal-title":"EMBO Mol Med"},{"issue":"19","key":"837_CR124","doi-asserted-by":"publisher","first-page":"7113","DOI":"10.3390\/ijms21197113","volume":"21","author":"G Kouroupi","year":"2020","unstructured":"Kouroupi G, Antoniou N, Prodromidou K, Taoufik E, Matsas R. Patient-Derived induced pluripotent stem Cell-Based models in Parkinson\u2019s disease for drug identification. Int J Mol Sci. 2020;21(19):7113.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"837_CR125","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/cells12040625","volume":"12","author":"A Becerra-Calixto","year":"2023","unstructured":"Becerra-Calixto A, Mukherjee A, Ramirez S, Sepulveda S, Sinha T, Al-Lahham R, et al. Lewy body-like pathology and loss of dopaminergic neurons in midbrain organoids derived from Familial Parkinson\u2019s disease patient. Cells. 2023;12(4):625.","journal-title":"Cells"},{"issue":"3","key":"837_CR126","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/ijms21030694","volume":"21","author":"P Chlebanowska","year":"2020","unstructured":"Chlebanowska P, Tejchman A, Su\u0142kowski M, Skrzypek K, Majka M. Use of 3D organoids as a model to study idiopathic form of Parkinson\u2019s disease. Int J Mol Sci. 2020;21(3):694.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"837_CR127","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/s41598-018-34828-3","volume":"9","author":"KIW Kane","year":"2019","unstructured":"Kane KIW, Moreno EL, Hachi S, Walter M, Jarazo J, Oliveira MAP, et al. Automated microfluidic cell culture of stem cell derived dopaminergic neurons. Sci Rep. 2019;9(1):1796.","journal-title":"Sci Rep"},{"key":"837_CR128","doi-asserted-by":"publisher","first-page":"e18648","DOI":"10.7554\/eLife.18648","volume":"5","author":"CJ Huh","year":"2016","unstructured":"Huh CJ, Zhang B, Victor MB, Dahiya S, Batista LF, Horvath S, et al. Maintenance of age in human neurons generated by microRNA-based neuronal conversion of fibroblasts. Elife. 2016;5:e18648.","journal-title":"Elife"},{"key":"837_CR129","first-page":"43","volume":"27","author":"L B\u00f6hnke","year":"2018","unstructured":"B\u00f6hnke L, Traxler L, Herdy JR, Mertens J. Human neurons to model aging: A dish best served old. Drug Discovery Today: Disease Models. 2018;27:43\u20139.","journal-title":"Drug Discovery Today: Disease Models"},{"issue":"10","key":"837_CR130","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.stemcr.2022.08.010","volume":"17","author":"J Drouin-Ouellet","year":"2022","unstructured":"Drouin-Ouellet J, Legault EM, Nilsson F, Pircs K, Bouquety J, Petit F, et al. Age-related pathological impairments in directly reprogrammed dopaminergic neurons derived from patients with idiopathic Parkinson\u2019s disease. Stem Cell Rep. 2022;17(10):2203\u201319.","journal-title":"Stem Cell Rep"},{"issue":"3","key":"837_CR131","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10072-023-07175-z","volume":"45","author":"YY Zheng","year":"2024","unstructured":"Zheng YY, Xu H, Wang YS. Progress in direct reprogramming of dopaminergic cell replacement therapy. Neurol Sci. 2024;45(3):873\u201381.","journal-title":"Neurol Sci"},{"key":"837_CR132","doi-asserted-by":"crossref","unstructured":"Calamini B, Geyer N, Huss-Braun N, Bernhardt A, Harsany V, Rival P et al. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson\u2019s disease. Dis Models Mech. 2021;14(6).","DOI":"10.1242\/dmm.048017"},{"key":"837_CR133","doi-asserted-by":"publisher","first-page":"1179086","DOI":"10.3389\/fnagi.2023.1179086","volume":"15","author":"SJ Fagen","year":"2023","unstructured":"Fagen SJ, Burgess JD, Lim MJ, Amerna D, Kaya ZB, Faroqi AH, et al. Honokiol decreases alpha-synuclein mRNA levels and reveals novel targets for modulating alpha-synuclein expression. Front Aging Neurosci. 2023;15:1179086.","journal-title":"Front Aging Neurosci"},{"key":"837_CR134","doi-asserted-by":"crossref","unstructured":"Mettai M, Daoud I, Melkemi N. In Silico Approaches for the Study of New Anti-Parkinson\u2019s Agents. Chemistry Proceedings. 2023;14(1):55.","DOI":"10.3390\/ecsoc-27-16067"},{"key":"837_CR135","doi-asserted-by":"crossref","unstructured":"Islam NN, Weber CA, Coban M, Cocker LT, Fiesel FC, Springer W et al. In Silico investigation of Parkin-Activating mutations using simulations and network modeling. Biomolecules. 2024;14(3).","DOI":"10.3390\/biom14030365"},{"key":"837_CR136","doi-asserted-by":"crossref","unstructured":"Denaro C, Stephenson D, M\u00fcller MLTM, Piccoli B, Azer K. Advancing precision medicine therapeutics for Parkinson\u2019s utilizing a shared quantitative systems Pharmacology model and framework. Front Syst Biology. 2024;4.","DOI":"10.3389\/fsysb.2024.1351555"},{"key":"837_CR137","doi-asserted-by":"crossref","unstructured":"Tuladhar A, Moore JA, Ismail Z, Forkert ND. Modeling neurodegeneration in Silico with deep learning. Front Neuroinformatics. 2021;15.","DOI":"10.3389\/fninf.2021.748370"},{"key":"837_CR138","unstructured":"Association As. 2024 Alzheimer\u2019s Disease Facts and Figures. In: Dementia As, editor. 2024."},{"issue":"4","key":"837_CR139","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41582-024-00940-4","volume":"20","author":"AD Korczyn","year":"2024","unstructured":"Korczyn AD, Grinberg LT. Is alzheimer disease a disease? Nat Rev Neurol. 2024;20(4):245\u201351.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"837_CR140","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathology Experimental Neurol. 2012;71(5):362\u201381.","journal-title":"J Neuropathology Experimental Neurol"},{"issue":"18","key":"837_CR141","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1016\/j.neuron.2022.06.021","volume":"110","author":"M Otero-Garcia","year":"2022","unstructured":"Otero-Garcia M, Mahajani SU, Wakhloo D, Tang W, Xue Y-Q, Morabito S, et al. Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer`s disease. Neuron. 2022;110(18):2929\u2013e488.","journal-title":"Neuron"},{"issue":"2","key":"837_CR142","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2017.08.013","volume":"14","author":"C Cruchaga","year":"2018","unstructured":"Cruchaga C, Del-Aguila JL, Saef B, Black K, Fernandez MV, Budde J, et al. Polygenic risk score of sporadic late-onset Alzheimer\u2019s disease reveals a shared architecture with the Familial and early-onset forms. Alzheimers Dement. 2018;14(2):205\u201314.","journal-title":"Alzheimers Dement"},{"key":"837_CR143","doi-asserted-by":"publisher","first-page":"102599","DOI":"10.1016\/j.arr.2024.102599","volume":"104","author":"HK Krishnamurthy","year":"2024","unstructured":"Krishnamurthy HK, Jayaraman V, Krishna K, Wang T, Bei K, Changalath C, et al. An overview of the genes and biomarkers in Alzheimer\u2019s disease. Ageing Res Rev. 2024;104:102599.","journal-title":"Ageing Res Rev"},{"issue":"6","key":"837_CR144","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00401-011-0879-y","volume":"122","author":"YS Davidson","year":"2011","unstructured":"Davidson YS, Raby S, Foulds PG, Robinson A, Thompson JC, Sikkink S, et al. TDP-43 pathological changes in early onset Familial and sporadic Alzheimer\u2019s disease, late onset Alzheimer\u2019s disease and Down\u2019s syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol. 2011;122(6):703\u201313.","journal-title":"Acta Neuropathol"},{"key":"837_CR145","doi-asserted-by":"publisher","first-page":"121918","DOI":"10.1016\/j.lfs.2023.121918","volume":"328","author":"S Ulaganathan","year":"2023","unstructured":"Ulaganathan S, Pitchaimani A. Spontaneous and Familial models of Alzheimer\u2019s disease: challenges and advances in preclinical research. Life Sci. 2023;328:121918.","journal-title":"Life Sci"},{"issue":"2","key":"837_CR146","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","volume":"133","author":"E Drummond","year":"2017","unstructured":"Drummond E, Wisniewski T. Alzheimer\u2019s disease: experimental models and reality. Acta Neuropathol. 2017;133(2):155\u201375.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"837_CR147","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.24272\/j.issn.2095-8137.2022.289","volume":"43","author":"Z-Y Chen","year":"2022","unstructured":"Chen Z-Y, Zhang Y. Animal models of Alzheimer\u2019s disease: applications, evaluation, and perspectives. Zoological Res. 2022;43(6):1026\u201340.","journal-title":"Zoological Res"},{"key":"837_CR148","doi-asserted-by":"crossref","unstructured":"Griffin EF, Scopel SE, Stephen CA, Holzhauer AC, Vaji MA, Tuckey RA et al. ApoE-associated modulation of neuroprotection from A\u03b2-mediated neurodegeneration in Transgenic Caenorhabditis elegans. Dis Models Mech. 2019;12(2).","DOI":"10.1242\/dmm.037218"},{"issue":"12","key":"837_CR149","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/dneu.20532","volume":"67","author":"D Knight","year":"2007","unstructured":"Knight D, Iliadi K, Charlton MP, Atwood HL, Boulianne GL. Presynaptic plasticity and associative learning are impaired in a Drosophila presenilin null mutant. Dev Neurobiol. 2007;67(12):1598\u2013613.","journal-title":"Dev Neurobiol"},{"issue":"5","key":"837_CR150","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/sj.npp.1301489","volume":"33","author":"JD Best","year":"2008","unstructured":"Best JD, Berghmans S, Hunt JJFG, Clarke SC, Fleming A, Goldsmith P, et al. Non-Associative learning in larval zebrafish. Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol. 2008;33(5):1206\u201315.","journal-title":"Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol"},{"issue":"9","key":"837_CR151","doi-asserted-by":"publisher","first-page":"e105862","DOI":"10.1371\/journal.pone.0105862","volume":"9","author":"LR Nery","year":"2014","unstructured":"Nery LR, Eltz NS, Hackman C, Fonseca R, Altenhofen S, Guerra HN, et al. Brain intraventricular injection of amyloid-\u03b2 in zebrafish embryo impairs cognition and increases Tau phosphorylation, effects reversed by lithium. PLoS ONE. 2014;9(9):e105862.","journal-title":"PLoS ONE"},{"issue":"10","key":"837_CR152","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","volume":"21","author":"TM Dawson","year":"2018","unstructured":"Dawson TM, Golde TE, Lagier-Tourenne C. Animal models of neurodegenerative diseases. Nat Neurosci. 2018;21(10):1370\u20139.","journal-title":"Nat Neurosci"},{"issue":"40","key":"837_CR153","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in Transgenic mice with five Familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129\u201340.","journal-title":"J Neurosci"},{"issue":"1","key":"837_CR154","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13073-018-0523-8","volume":"10","author":"KE Tansey","year":"2018","unstructured":"Tansey KE, Cameron D, Hill MJ. Genetic risk for Alzheimer\u2019s disease is concentrated in specific macrophage and microglial transcriptional networks. Genome Med. 2018;10(1):14.","journal-title":"Genome Med"},{"issue":"5","key":"837_CR155","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.neuron.2010.04.031","volume":"66","author":"KH Ashe","year":"2010","unstructured":"Ashe KH, Zahs KR. Probing the biology of Alzheimer\u2019s disease in mice. Neuron. 2010;66(5):631\u201345.","journal-title":"Neuron"},{"key":"837_CR156","doi-asserted-by":"crossref","unstructured":"LaFerla FM, Green KN. Animal models of alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(11).","DOI":"10.1101\/cshperspect.a006320"},{"issue":"1","key":"837_CR157","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev.genet.32.1.461","volume":"32","author":"DL Price","year":"1998","unstructured":"Price DL, Tanzi RE, Borchelt DR, Sisodia SS. Alzheimer\u2019s disease: genetic studies and Transgenic models. Annu Rev Genet. 1998;32(1):461\u201393.","journal-title":"Annu Rev Genet"},{"key":"837_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1326-8-15","volume":"8","author":"J Kim","year":"2013","unstructured":"Kim J, Chakrabarty P, Hanna A, March A, Dickson DW, Borchelt DR, et al. Normal cognition in Transgenic BRI2-A\u03b2 mice. Mol Neurodegeneration. 2013;8:1\u201312.","journal-title":"Mol Neurodegeneration"},{"issue":"5","key":"837_CR159","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nn.3697","volume":"17","author":"T Saito","year":"2014","unstructured":"Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, et al. Single app knock-in mouse models of Alzheimer\u2019s disease. Nat Neurosci. 2014;17(5):661\u20133.","journal-title":"Nat Neurosci"},{"issue":"3","key":"837_CR160","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1046\/j.1471-4159.2003.01879.x","volume":"86","author":"C Andorfer","year":"2003","unstructured":"Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, et al. Hyperphosphorylation and aggregation of Tau in mice expressing normal human Tau isoforms. J Neurochem. 2003;86(3):582\u201390.","journal-title":"J Neurochem"},{"issue":"3","key":"837_CR161","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409\u201321.","journal-title":"Neuron"},{"issue":"6","key":"837_CR162","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.24272\/j.issn.2095-8137.2022.289","volume":"43","author":"ZY Chen","year":"2022","unstructured":"Chen ZY, Zhang Y. Animal models of Alzheimer\u2019s disease: applications, evaluation, and perspectives. Zool Res. 2022;43(6):1026\u201340.","journal-title":"Zool Res"},{"issue":"5","key":"837_CR163","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.neuron.2017.02.001","volume":"93","author":"I Espuny-Camacho","year":"2017","unstructured":"Espuny-Camacho I, Arranz AM, Fiers M, Snellinx A, Ando K, Munck S, et al. Hallmarks of Alzheimer\u2019s disease in Stem-Cell-Derived human neurons transplanted into mouse brain. Neuron. 2017;93(5):1066\u2013e818.","journal-title":"Neuron"},{"issue":"5","key":"837_CR164","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/s41593-024-01600-y","volume":"27","author":"R Mancuso","year":"2024","unstructured":"Mancuso R, Fattorelli N, Martinez-Muriana A, Davis E, Wolfs L, Van Den Daele J, et al. Xenografted human microglia display diverse transcriptomic States in response to Alzheimer\u2019s disease-related amyloid-\u03b2 pathology. Nat Neurosci. 2024;27(5):886\u2013900.","journal-title":"Nat Neurosci"},{"key":"837_CR165","doi-asserted-by":"crossref","unstructured":"Hasselmann J, Coburn MA, England W, Figueroa Velez DX, Kiani Shabestari S, Tu CH,et al. Development of a Chimeric Model to Study and Manipulate Human Microglia\u2009<\u2009em\u2009>\u2009In\u00a0Vivo.Neuron. 2019;103(6):1016-33.e10.","DOI":"10.1016\/j.neuron.2019.07.002"},{"issue":"9","key":"837_CR166","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.embor.7400784","volume":"7","author":"R Radde","year":"2006","unstructured":"Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. A\u03b242-driven cerebral amyloidosis in Transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7(9):940\u20136.","journal-title":"EMBO Rep"},{"issue":"20","key":"837_CR167","doi-asserted-by":"publisher","first-page":"9382","DOI":"10.1073\/pnas.91.20.9382","volume":"91","author":"M Gearing","year":"1994","unstructured":"Gearing M, Rebeck GW, Hyman BT, Tigges J, Mirra SS. Neuropathology and Apolipoprotein E profile of aged chimpanzees: implications for alzheimer disease. Proc Natl Acad Sci USA. 1994;91(20):9382\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"837_CR168","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cne.21744","volume":"509","author":"RF Rosen","year":"2008","unstructured":"Rosen RF, Farberg AS, Gearing M, Dooyema J, Long M, Anderson P. Tauopathy with paired helical filaments in an aged chimpanzee. J Comp Neurol. 2008;509(3):259\u201370.","journal-title":"J Comp Neurol"},{"issue":"41","key":"837_CR169","doi-asserted-by":"publisher","first-page":"13629","DOI":"10.1523\/JNEUROSCI.1353-14.2014","volume":"34","author":"L Forny-Germano","year":"2014","unstructured":"Forny-Germano L, Lyra e Silva NM, Batista AF, Brito-Moreira J, Gralle M, Boehnke SE, et al. Alzheimer\u2019s disease-like pathology induced by amyloid-\u03b2 oligomers in nonhuman primates. J Neurosci. 2014;34(41):13629\u201343.","journal-title":"J Neurosci"},{"issue":"3","key":"837_CR170","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11011-010-9207-9","volume":"25","author":"W Li","year":"2010","unstructured":"Li W, Wu Y, Min F, Li Z, Huang J, Huang R. A nonhuman primate model of Alzheimer\u2019s disease generated by intracranial injection of amyloid-\u03b242 and thiorphan. Metab Brain Dis. 2010;25(3):277\u201384.","journal-title":"Metab Brain Dis"},{"issue":"2","key":"837_CR171","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00401-002-0626-5","volume":"105","author":"S Sani","year":"2003","unstructured":"Sani S, Traul D, Klink A, Niaraki N, Gonzalo-Ruiz A, Wu CK, et al. Distribution, progression and chemical composition of cortical amyloid-beta deposits in aged rhesus monkeys: similarities to the human. Acta Neuropathol. 2003;105(2):145\u201356.","journal-title":"Acta Neuropathol"},{"issue":"12","key":"837_CR172","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","volume":"66","author":"DA Bennett","year":"2006","unstructured":"Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837\u201344.","journal-title":"Neurology"},{"issue":"6","key":"837_CR173","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/alz.12318","volume":"17","author":"D Beckman","year":"2021","unstructured":"Beckman D, Chakrabarty P, Ott S, Dao A, Zhou E, Janssen WG, et al. A novel tau-based rhesus monkey model of Alzheimer\u2019s pathogenesis. Alzheimers Dement. 2021;17(6):933\u201345.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"837_CR174","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1742-2094-9-115","volume":"9","author":"B Stansley","year":"2012","unstructured":"Stansley B, Post J, Hensley K. A comparative review of cell culture systems for the study of microglial biology in Alzheimer\u2019s disease. J Neuroinflamm. 2012;9(1):115.","journal-title":"J Neuroinflamm"},{"issue":"6","key":"837_CR175","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/stem.2995","volume":"37","author":"W Haenseler","year":"2019","unstructured":"Haenseler W, Rajendran L. Concise review: modeling neurodegenerative diseases with human pluripotent stem cell-derived microglia. Stem Cells. 2019;37(6):724\u201330.","journal-title":"Stem Cells"},{"issue":"1","key":"837_CR176","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nn.3599","volume":"17","author":"O Butovsky","year":"2014","unstructured":"Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, et al. Identification of a unique TGF-\u03b2\u2013dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17(1):131\u201343.","journal-title":"Nat Neurosci"},{"issue":"7384","key":"837_CR177","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nature10821","volume":"482","author":"MA Israel","year":"2012","unstructured":"Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, et al. Probing sporadic and Familial Alzheimer\u2019s disease using induced pluripotent stem cells. Nature. 2012;482(7384):216\u201320.","journal-title":"Nature"},{"issue":"4","key":"837_CR178","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.stem.2013.01.009","volume":"12","author":"T Kondo","year":"2013","unstructured":"Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, et al. Modeling Alzheimer`s disease with iPSCs reveals stress phenotypes associated with intracellular A\u03b2 and differential drug responsiveness. Cell Stem Cell. 2013;12(4):487\u201396.","journal-title":"Cell Stem Cell"},{"issue":"13","key":"837_CR179","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1093\/hmg\/ddu064","volume":"23","author":"CR Muratore","year":"2014","unstructured":"Muratore CR, Rice HC, Srikanth P, Callahan DG, Shin T, Benjamin LN, et al. The Familial Alzheimer\u2019s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum Mol Genet. 2014;23(13):3523\u201336.","journal-title":"Hum Mol Genet"},{"issue":"23","key":"837_CR180","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1093\/hmg\/ddr394","volume":"20","author":"T Yagi","year":"2011","unstructured":"Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, et al. Modeling Familial Alzheimer\u2019s disease with induced pluripotent stem cells. Hum Mol Genet. 2011;20(23):4530\u20139.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"837_CR181","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.stem.2015.09.001","volume":"17","author":"J Mertens","year":"2015","unstructured":"Mertens J, Paquola AC, Ku M, Hatch E, B\u00f6hnke L, Ladjevardi S, et al. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell. 2015;17(6):705\u201318.","journal-title":"Cell Stem Cell"},{"issue":"9","key":"837_CR182","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.stem.2021.04.004","volume":"28","author":"J Mertens","year":"2021","unstructured":"Mertens J, Herdy JR, Traxler L, Schafer ST, Schlachetzki JCM, B\u00f6hnke L, et al. Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer`s patients. Cell Stem Cell. 2021;28(9):1533\u2013e486.","journal-title":"Cell Stem Cell"},{"issue":"12","key":"837_CR183","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.stem.2022.11.010","volume":"29","author":"JR Herdy","year":"2022","unstructured":"Herdy JR, Traxler L, Agarwal RK, Karbacher L, Schlachetzki JCM, Boehnke L, et al. Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer`s disease. Cell Stem Cell. 2022;29(12):1637\u2013e526.","journal-title":"Cell Stem Cell"},{"issue":"8","key":"837_CR184","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1093\/brain\/awx144","volume":"140","author":"H Kim","year":"2017","unstructured":"Kim H, Yoo J, Shin J, Chang Y, Jung J, Jo D-G, et al. Modelling APOE \u01903\/4 allele-associated sporadic Alzheimer\u2019s disease in an induced neuron. Brain. 2017;140(8):2193\u2013209.","journal-title":"Brain"},{"issue":"1","key":"837_CR185","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40035-022-00319-9","volume":"11","author":"H Kim","year":"2022","unstructured":"Kim H, Kim S, Cho B, Shin J, Kim J. APOE \u03b54-dependent effects on the early amyloid pathology in induced neurons of patients with Alzheimer\u2019s disease. Translational Neurodegeneration. 2022;11(1):45.","journal-title":"Translational Neurodegeneration"},{"issue":"7601","key":"837_CR186","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nature17664","volume":"533","author":"D Paquet","year":"2016","unstructured":"Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR\/Cas9. Nature. 2016;533(7601):125\u20139.","journal-title":"Nature"},{"issue":"1","key":"837_CR187","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41380-019-0468-3","volume":"25","author":"J Penney","year":"2020","unstructured":"Penney J, Ralvenius WT, Tsai L-H. Modeling Alzheimer\u2019s disease with iPSC-derived brain cells. Mol Psychiatry. 2020;25(1):148\u201367.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"837_CR188","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13287-024-03737-w","volume":"15","author":"Z Cao","year":"2024","unstructured":"Cao Z, Kong F, Ding J, Chen C, He F, Deng W. Promoting Alzheimer\u2019s disease research and therapy with stem cell technology. Stem Cell Res Ther. 2024;15(1):136.","journal-title":"Stem Cell Res Ther"},{"issue":"7526","key":"837_CR189","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nature13800","volume":"515","author":"SH Choi","year":"2014","unstructured":"Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D\u2019Avanzo C, et al. A three-dimensional human neural cell culture model of Alzheimer\u2019s disease. Nature. 2014;515(7526):274\u20138.","journal-title":"Nature"},{"issue":"7","key":"837_CR190","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nprot.2015.065","volume":"10","author":"YH Kim","year":"2015","unstructured":"Kim YH, Choi SH, D\u2019Avanzo C, Hebisch M, Sliwinski C, Bylykbashi E, et al. A 3D human neural cell culture system for modeling Alzheimer\u2019s disease. Nat Protoc. 2015;10(7):985\u20131006.","journal-title":"Nat Protoc"},{"issue":"18","key":"837_CR191","doi-asserted-by":"publisher","first-page":"2101462","DOI":"10.1002\/advs.202101462","volume":"8","author":"X Chen","year":"2021","unstructured":"Chen X, Sun G, Tian E, Zhang M, Davtyan H, Beach TG, et al. Modeling sporadic Alzheimer\u2019s disease in human brain organoids under serum exposure. Adv Sci. 2021;8(18):2101462.","journal-title":"Adv Sci"},{"issue":"6708","key":"837_CR192","doi-asserted-by":"publisher","first-page":"adl2992","DOI":"10.1126\/science.adl2992","volume":"385","author":"Z Sun","year":"2024","unstructured":"Sun Z, Kwon J-S, Ren Y, Chen S, Walker CK, Lu X, et al. Modeling late-onset Alzheimer\u2019s disease neuropathology via direct neuronal reprogramming. Science. 2024;385(6708):adl2992.","journal-title":"Science"},{"issue":"2","key":"837_CR193","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12015-021-10254-3","volume":"18","author":"M Barak","year":"2022","unstructured":"Barak M, Fedorova V, Pospisilova V, Raska J, Vochyanova S, Sedmik J, et al. Human iPSC-Derived neural models for studying Alzheimer\u2019s disease: from neural stem cells to cerebral organoids. Stem Cell Reviews Rep. 2022;18(2):792\u2013820.","journal-title":"Stem Cell Reviews Rep"},{"issue":"1","key":"837_CR194","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13195-017-0317-z","volume":"9","author":"A Ochalek","year":"2017","unstructured":"Ochalek A, Mihalik B, Avci HX, Chandrasekaran A, T\u00e9gl\u00e1si A, Bock I, et al. Neurons derived from sporadic Alzheimer\u2019s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation. Alzheimers Res Ther. 2017;9(1):90.","journal-title":"Alzheimers Res Ther"},{"key":"837_CR195","doi-asserted-by":"crossref","unstructured":"Yefroyev DA, Jin S. Induced Pluripotent Stem Cells for Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases. Biomedicines. 2022;10(2).","DOI":"10.3390\/biomedicines10020208"},{"issue":"2","key":"837_CR196","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.stem.2015.07.006","volume":"17","author":"W Hu","year":"2015","unstructured":"Hu W, Qiu B, Guan W, Wang Q, Wang M, Li W, et al. Direct conversion of normal and Alzheimer`s disease human fibroblasts into neuronal cells by small molecules. Cell Stem Cell. 2015;17(2):204\u201312.","journal-title":"Cell Stem Cell"},{"key":"837_CR197","unstructured":"Yang F, Chowdhury SR, Jacobs HI, Johnson KA, Dutta J, editors. A longitudinal model for tau aggregation in Alzheimer\u2019s disease based on structural connectivity. Information Processing in Medical Imaging: 26th International Conference, IPMI 2019, Hong Kong, China, June 2\u20137, 2019, Proceedings 26; 2019: Springer."},{"issue":"8","key":"837_CR198","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.3390\/ijms19082415","volume":"19","author":"DM\u00c1 Villalobos Acosta","year":"2018","unstructured":"Villalobos Acosta DM\u00c1, Chimal Vega B, Correa Basurto J, Fragoso Morales LG, Rosales Hern\u00e1ndez MC. Recent advances by in Silico and in vitro studies of amyloid-\u03b2 1\u201342 fibril depicted a S-shape conformation. Int J Mol Sci. 2018;19(8):2415.","journal-title":"Int J Mol Sci"},{"issue":"6359","key":"837_CR199","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1126\/science.aao2825","volume":"358","author":"L Gremer","year":"2017","unstructured":"Gremer L, Sch\u00f6lzel D, Schenk C, Reinartz E, Labahn J, Ravelli RB, et al. Fibril structure of amyloid-\u03b2 (1\u201342) by cryo\u2013electron microscopy. Science. 2017;358(6359):116\u20139.","journal-title":"Science"},{"issue":"1","key":"837_CR200","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1038\/s41467-019-12683-8","volume":"10","author":"M Kollmer","year":"2019","unstructured":"Kollmer M, Close W, Funk L, Rasmussen J, Bsoul A, Schierhorn A, et al. Cryo-EM structure and polymorphism of A\u03b2 amyloid fibrils purified from Alzheimer\u2019s brain tissue. Nat Commun. 2019;10(1):4760.","journal-title":"Nat Commun"},{"issue":"3","key":"837_CR201","doi-asserted-by":"publisher","first-page":"e22184","DOI":"10.1002\/ddr.22184","volume":"85","author":"D Akkaya","year":"2024","unstructured":"Akkaya D, Seyhan G, Sari S, Barut B. In vitro and in Silico investigation of FDA-approved drugs to be repurposed against Alzheimer\u2019s disease. Drug Dev Res. 2024;85(3):e22184.","journal-title":"Drug Dev Res"},{"issue":"1","key":"837_CR202","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/ijms12010694","volume":"12","author":"P Kumar","year":"2011","unstructured":"Kumar P, Pillay V, Choonara YE, Modi G, Naidoo D, Du Toit LC. Silico theoretical molecular modeling for Alzheimer\u2019s disease: the Nicotine-Curcumin paradigm in neuroprotection and neurotherapy. Int J Mol Sci. 2011;12(1):694\u2013724.","journal-title":"Int J Mol Sci"},{"key":"837_CR203","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijbiomac.2020.04.007","volume":"156","author":"R-z Nie","year":"2020","unstructured":"Nie R-z, Huo Y-q, Yu B, Liu C-j, Zhou R, Bao H-h, et al. Molecular insights into the inhibitory mechanisms of gallate moiety on the A\u03b21\u201340 amyloid aggregation: A molecular dynamics simulation study. Int J Biol Macromol. 2020;156:40\u201350.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"837_CR204","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1479-5876-10-217","volume":"10","author":"I Greco","year":"2012","unstructured":"Greco I, Day N, Riddoch-Contreras J, Reed J, Soininen H, K\u0142oszewska I, et al. Alzheimer\u2019s disease biomarker discovery using in Silico literature mining and clinical validation. J Translational Med. 2012;10(1):217.","journal-title":"J Translational Med"},{"key":"837_CR205","doi-asserted-by":"publisher","first-page":"1348113","DOI":"10.3389\/fninf.2024.1348113","volume":"18","author":"\u00c9 Chamberland","year":"2024","unstructured":"Chamberland \u00c9, Moravveji S, Doyon N, Duchesne S. A computational model of Alzheimer\u2019s disease at the Nano, micro, and macroscales. Front Neuroinform. 2024;18:1348113.","journal-title":"Front Neuroinform"},{"issue":"S1","key":"837_CR206","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1017\/cjn.2016.2","volume":"43","author":"DB Hogan","year":"2016","unstructured":"Hogan DB, Fiest KM, Roberts JI, Maxwell CJ, Dykeman J, Pringsheim T, et al. The prevalence and incidence of dementia with lewy bodies: a systematic review. Can J Neurol Sci \/ J Canadien Des Sci Neurologiques. 2016;43(S1):S83\u201395.","journal-title":"Can J Neurol Sci \/ J Canadien Des Sci Neurologiques"},{"issue":"3","key":"837_CR207","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1042\/BST20180466","volume":"47","author":"TF Outeiro","year":"2019","unstructured":"Outeiro TF, Harvey K, Dominguez-Meijide A, Gerhardt E. LRRK2, alpha-synuclein, and Tau: partners in crime or unfortunate bystanders? Biochem Soc Trans. 2019;47(3):827\u201338.","journal-title":"Biochem Soc Trans"},{"issue":"3","key":"837_CR208","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-018-1953-5","volume":"137","author":"C Vergara","year":"2019","unstructured":"Vergara C, Houben S, Suain V, Yilmaz Z, De Decker R, Vanden Dries V, et al. Amyloid-\u03b2 pathology enhances pathological fibrillary Tau seeding induced by alzheimer PHF in vivo. Acta Neuropathol. 2019;137(3):397\u2013412.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"837_CR209","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Tredici KD, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24(2):197\u2013211.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"837_CR210","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res. 2004;318(1):121\u201334.","journal-title":"Cell Tissue Res"},{"issue":"4","key":"837_CR211","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim S, Kwon S-H, Kam T-I, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal propagation of pathologic \u03b1-Synuclein from the gut to the brain models Parkinson\u2019s disease. Neuron. 2019;103(4):627\u2013e417.","journal-title":"Neuron"},{"issue":"10","key":"837_CR212","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11910-018-0874-y","volume":"18","author":"T Orme","year":"2018","unstructured":"Orme T, Guerreiro R, Bras J. The genetics of dementia with lewy bodies: current Understanding and future directions. Curr Neurol Neurosci Rep. 2018;18(10):67.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"21","key":"837_CR213","doi-asserted-by":"publisher","first-page":"12245","DOI":"10.1073\/pnas.211412398","volume":"98","author":"E Masliah","year":"2001","unstructured":"Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. \u03b2-Amyloid peptides enhance \u03b1-synuclein accumulation and neuronal deficits in a Transgenic mouse model linking Alzheimer\u2019s disease and Parkinson\u2019s disease. Proc Natl Acad Sci. 2001;98(21):12245\u201350.","journal-title":"Proc Natl Acad Sci"},{"key":"837_CR214","doi-asserted-by":"crossref","unstructured":"Hsia AY, Masliah E, McConlogue L, Yu G-Q, Tatsuno G, Hu K et al. Plaque-independent disruption of neural circuits in Alzheimer\u2019s disease mouse models. Proceedings of the National Academy of Sciences. 1999;96(6):3228-33.","DOI":"10.1073\/pnas.96.6.3228"},{"issue":"5456","key":"837_CR215","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","volume":"287","author":"E Masliah","year":"2000","unstructured":"Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in \u03b1-Synuclein mice: implications for neurodegenerative disorders. Science. 2000;287(5456):1265\u20139.","journal-title":"Science"},{"issue":"5619","key":"837_CR216","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1126\/science.1082324","volume":"300","author":"BI Giasson","year":"2003","unstructured":"Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al. Initiation and synergistic fibrillization of Tau and alpha-synuclein. Science. 2003;300(5619):636\u201340.","journal-title":"Science"},{"issue":"2","key":"837_CR217","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuron.2019.10.010","volume":"105","author":"F Bassil","year":"2020","unstructured":"Bassil F, Brown HJ, Pattabhiraman S, Iwasyk JE, Maghames CM, Meymand ES, et al. Amyloid-Beta (A\u03b2) plaques promote seeding and spreading of Alpha-Synuclein and Tau in a mouse model of lewy body disorders with A\u03b2 pathology. Neuron. 2020;105(2):260\u2013.\u2013\u200975.e6.","journal-title":"Neuron"},{"issue":"1","key":"837_CR218","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-021-00486-9","volume":"16","author":"GM Lloyd","year":"2021","unstructured":"Lloyd GM, Dhillon J-KS, Gorion K-MM, Riffe C, Fromholt SE, Xia Y, et al. Collusion of \u03b1-Synuclein and A\u03b2 aggravating co-morbidities in a novel prion-type mouse model. Mol Neurodegeneration. 2021;16(1):63.","journal-title":"Mol Neurodegeneration"},{"issue":"7","key":"837_CR219","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/nm.3885","volume":"21","author":"T Bachhuber","year":"2015","unstructured":"Bachhuber T, Katzmarski N, McCarter JF, Loreth D, Tahirovic S, Kamp F, et al. Inhibition of amyloid-\u03b2 plaque formation by \u03b1-synuclein. Nat Med. 2015;21(7):802\u20137.","journal-title":"Nat Med"},{"issue":"4","key":"837_CR220","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00401-018-1886-z","volume":"136","author":"SS Khan","year":"2018","unstructured":"Khan SS, LaCroix M, Boyle G, Sherman MA, Brown JL, Amar F, et al. Bidirectional modulation of alzheimer phenotype by alpha-synuclein in mice and primary neurons. Acta Neuropathol. 2018;136(4):589\u2013605.","journal-title":"Acta Neuropathol"},{"issue":"10","key":"837_CR221","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.3390\/biomedicines11102863","volume":"11","author":"MJ Lim","year":"2023","unstructured":"Lim MJ, Boschen SL, Kurti A, Castanedes Casey M, Phillips VR, Fryer JD, et al. Investigating the pathogenic interplay of Alpha-Synuclein, Tau, and amyloid Beta in lewy body dementia: insights from Viral-Mediated overexpression in Transgenic mouse models. Biomedicines. 2023;11(10):2863.","journal-title":"Biomedicines"},{"issue":"37","key":"837_CR222","doi-asserted-by":"publisher","first-page":"eadk3700","DOI":"10.1126\/sciadv.adk3700","volume":"10","author":"Y Jin","year":"2024","unstructured":"Jin Y, Li F, Li Z, Ikezu TC, O\u2019Leary J, Selvaraj M, et al. Modeling lewy body disease with <\u2009i\u2009>\u2009snca\u2009triplication iPSC-derived cortical organoids and identifying therapeutic drugs. Sci Adv. 2024;10(37):eadk3700.","journal-title":"Sci Adv"},{"issue":"12","key":"837_CR223","doi-asserted-by":"publisher","first-page":"2100097","DOI":"10.1002\/anbr.202100097","volume":"1","author":"NS Sharma","year":"2021","unstructured":"Sharma NS, Karan A, Lee D, Yan Z, Xie J. Advances in modeling Alzheimer\u2019s disease in vitro. Adv NanoBiomed Res. 2021;1(12):2100097.","journal-title":"Adv NanoBiomed Res"},{"issue":"1","key":"837_CR224","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1038\/s41467-024-46554-8","volume":"15","author":"S Amartumur","year":"2024","unstructured":"Amartumur S, Nguyen H, Huynh T, Kim TS, Woo R-S, Oh E, et al. Neuropathogenesis-on-chips for neurodegenerative diseases. Nat Commun. 2024;15(1):2219.","journal-title":"Nat Commun"},{"issue":"11","key":"837_CR225","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41582-022-00723-9","volume":"18","author":"OL Eichm\u00fcller","year":"2022","unstructured":"Eichm\u00fcller OL, Knoblich JA. Human cerebral organoids \u2014 a new tool for clinical neurology research. Nat Reviews Neurol. 2022;18(11):661\u201380.","journal-title":"Nat Reviews Neurol"},{"issue":"45, 2022","key":"837_CR226","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev-neuro-111020-090812","volume":"45","author":"MG Andrews","year":"2022","unstructured":"Andrews MG, Kriegstein AR. Challenges of organoid research. Annu Rev Neurosci. 2022;45(45, 2022):23\u201339.","journal-title":"Annu Rev Neurosci"},{"issue":"2","key":"837_CR227","doi-asserted-by":"publisher","first-page":"263","DOI":"10.24272\/j.issn.2095-8137.2023.197","volume":"45","author":"M-T Pan","year":"2024","unstructured":"Pan M-T, Zhang H, Li X-J, Guo X-Y. Genetically modified non-human primate models for research on neurodegenerative diseases. Zoological Res. 2024;45(2):263\u201374.","journal-title":"Zoological Res"},{"issue":"9618","key":"837_CR228","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(08)60489-4","volume":"371","author":"JP Capitanio","year":"2008","unstructured":"Capitanio JP, Emborg ME. Contributions of non-human primates to neuroscience research. Lancet. 2008;371(9618):1126\u201335.","journal-title":"Lancet"},{"key":"837_CR229","doi-asserted-by":"publisher","first-page":"100064","DOI":"10.1016\/j.crneur.2022.100064","volume":"4","author":"P Janssen","year":"2023","unstructured":"Janssen P, Isa T, Lanciego J, Leech K, Logothetis N, Poo M-M, et al. Visualizing advances in the future of primate neuroscience research. Curr Res Neurobiol. 2023;4:100064.","journal-title":"Curr Res Neurobiol"},{"issue":"3","key":"837_CR230","first-page":"278","volume":"53","author":"EW Lankau","year":"2014","unstructured":"Lankau EW, Turner PV, Mullan RJ, Galland GG. Use of nonhuman primates in research in North America. J Am Assoc Lab Anim Sci. 2014;53(3):278\u201382.","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"837_CR231","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1006\/exnr.1998.6848","volume":"152","author":"DR Kirik","year":"1998","unstructured":"Kirik DR, Bjorklund C. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol. 1998;152:18.","journal-title":"Exp Neurol"},{"key":"837_CR232","doi-asserted-by":"crossref","unstructured":"Carvalho MM, Campos FL, Coimbra B, P\u00eago JM, Rodrigues C, Lima R et al. Behavioral characterization of the 6-hydroxidopamine model of Parkinson\u2019s disease and pharmacological rescuing of non-motor deficits. Mol Neurodegeneration. 2013;8.","DOI":"10.1186\/1750-1326-8-14"},{"issue":"1","key":"837_CR233","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1038\/s41598-024-54066-0","volume":"14","author":"J Cui","year":"2024","unstructured":"Cui J, Zhao D, Xu M, Li Z, Qian J, Song N, et al. Characterization of graded 6-Hydroxydopamine unilateral lesion in medial forebrain bundle of mice. Sci Rep. 2024;14(1):3721.","journal-title":"Sci Rep"},{"key":"837_CR234","doi-asserted-by":"publisher","first-page":"111981","DOI":"10.1016\/j.bbr.2019.111981","volume":"371","author":"JCF Vieira","year":"2019","unstructured":"Vieira JCF, Bassani TB, Santiago RM, de Zanoveli OGG, da Cunha JM. Anxiety-like behavior induced by 6-OHDA animal model of Parkinson\u2019s disease May be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety. Behav Brain Res. 2019;371:111981.","journal-title":"Behav Brain Res"},{"issue":"2","key":"837_CR235","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0006-8993(93)90049-S","volume":"615","author":"J Schneider","year":"1993","unstructured":"Schneider J, Roeltgen D. Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. Brain Res. 1993;615(2):351\u20134.","journal-title":"Brain Res"},{"key":"837_CR236","doi-asserted-by":"crossref","unstructured":"Fornai F, Schl\u00fcter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and \u03b1-synuclein. Proceedings of the National Academy of Sciences. 2005;102(9):3413-8.","DOI":"10.1073\/pnas.0409713102"},{"issue":"2","key":"837_CR237","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0893-133X(01)00307-4","volume":"26","author":"JS Schneider","year":"2002","unstructured":"Schneider JS, Giardiniere M, Morain P. Effects of the Prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-Treated monkeys. Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol. 2002;26(2):176\u201382.","journal-title":"Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol"},{"issue":"8","key":"837_CR238","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/NEN.0b013e318180f0bd","volume":"67","author":"AL McCormack","year":"2008","unstructured":"McCormack AL, Mak SK, Shenasa M, Langston WJ, Forno LS, Di Monte DA. Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol. 2008;67(8):793\u2013802.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"8","key":"837_CR239","doi-asserted-by":"publisher","first-page":"e23952","DOI":"10.1371\/journal.pone.0023952","volume":"6","author":"J Vezoli","year":"2011","unstructured":"Vezoli J, Fifel K, Leviel V, Dehay C, Kennedy H, Cooper HM, et al. Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson\u2019s disease. PLoS ONE. 2011;6(8):e23952.","journal-title":"PLoS ONE"},{"issue":"6","key":"837_CR240","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1037\/a0017401","volume":"123","author":"WF Wang","year":"2009","unstructured":"Wang WF, Wu SL, Liou YM, Wang AL, Pawlak CR, Ho YJ. MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats. Behav Neurosci. 2009;123(6):1261\u201370.","journal-title":"Behav Neurosci"},{"issue":"1","key":"837_CR241","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/00001756-200001170-00041","volume":"11","author":"NW Kowall","year":"2000","unstructured":"Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ. MPTP induces alpha-synuclein aggregation in the substantia Nigra of baboons. NeuroReport. 2000;11(1):211\u20133.","journal-title":"NeuroReport"},{"issue":"2","key":"837_CR242","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.nbd.2009.01.016","volume":"34","author":"JR Cannon","year":"2009","unstructured":"Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson\u2019s disease. Neurobiol Dis. 2009;34(2):279\u201390.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"837_CR243","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.nbd.2009.06.017","volume":"36","author":"RE Drolet","year":"2009","unstructured":"Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces Parkinson\u2019s disease Gastrointestinal neuropathology. Neurobiol Dis. 2009;36(1):96\u2013102.","journal-title":"Neurobiol Dis"},{"key":"837_CR244","doi-asserted-by":"publisher","first-page":"105685","DOI":"10.1016\/j.nbd.2022.105685","volume":"167","author":"SM Rocha","year":"2022","unstructured":"Rocha SM, Bantle CM, Aboellail T, Chatterjee D, Smeyne RJ, Tjalkens RB. Rotenone induces regionally distinct \u03b1-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl\/6 mice. Neurobiol Dis. 2022;167:105685.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"837_CR245","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12974-020-02065-z","volume":"18","author":"D Zhang","year":"2021","unstructured":"Zhang D, Li S, Hou L, Jing L, Ruan Z, Peng B, et al. Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson\u2019s disease model. J Neuroinflamm. 2021;18(1):4.","journal-title":"J Neuroinflamm"},{"key":"837_CR246","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.neuro.2018.02.013","volume":"65","author":"ME Johnson","year":"2018","unstructured":"Johnson ME, Stringer A, Bobrovskaya L. Rotenone induces Gastrointestinal pathology and microbiota alterations in a rat model of Parkinson\u2019s disease. Neurotoxicology. 2018;65:174\u201385.","journal-title":"Neurotoxicology"},{"issue":"1","key":"837_CR247","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40478-017-0416-x","volume":"5","author":"CW Ip","year":"2017","unstructured":"Ip CW, Klaus L-C, Karikari AA, Visanji NP, Brotchie JM, Lang AE, et al. AAV1\/2-induced overexpression of A53T-\u03b1-synuclein in the substantia Nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson\u2019s disease. Acta Neuropathol Commun. 2017;5(1):11.","journal-title":"Acta Neuropathol Commun"},{"key":"837_CR248","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.expneurol.2015.09.002","volume":"273","author":"D Caudal","year":"2015","unstructured":"Caudal D, Alvarsson A, Bj\u00f6rklund A, Svenningsson P. Depressive-like phenotype induced by AAV-mediated overexpression of human \u03b1-synuclein in midbrain dopaminergic neurons. Exp Neurol. 2015;273:243\u201352.","journal-title":"Exp Neurol"},{"issue":"10","key":"837_CR249","doi-asserted-by":"publisher","first-page":"100876","DOI":"10.1016\/j.crmeth.2024.100876","volume":"4","author":"S Liu","year":"2024","unstructured":"Liu S, Yang N, Yan Y, Wang S, Chen J, Wang Y, et al. An accelerated Parkinson\u2019s disease monkey model using AAV-\u03b1-synuclein plus poly(ADP-ribose). Cell Rep Methods. 2024;4(10):100876.","journal-title":"Cell Rep Methods"},{"issue":"3","key":"837_CR250","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14802\/jmd.19046","volume":"12","author":"HK Chung","year":"2019","unstructured":"Chung HK, Ho HA, P\u00e9rez-Acu\u00f1a D, Lee SJ. Modeling \u03b1-Synuclein propagation with preformed fibril injections. J Mov Disord. 2019;12(3):139\u201351.","journal-title":"J Mov Disord"},{"key":"837_CR251","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-017-0494-9","volume":"5","author":"AS Harms","year":"2017","unstructured":"Harms AS, Delic V, Thome AD, Bryant N, Liu Z, Chandra S, et al. \u03b1-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. Acta Neuropathol Commun. 2017;5:1\u201316.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"837_CR252","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/awt037","volume":"136","author":"M Masuda-Suzukake","year":"2013","unstructured":"Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, et al. Prion-like spreading of pathological \u03b1-synuclein in brain. Brain. 2013;136(4):1128\u201338.","journal-title":"Brain"},{"issue":"5","key":"837_CR253","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.20112457","volume":"209","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm VM, Zhang B, O\u2019Brien P, Trojanowski JQ, Lee VMY. Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice. J Exp Med. 2012;209(5):975\u201386.","journal-title":"J Exp Med"},{"issue":"6","key":"837_CR254","doi-asserted-by":"publisher","first-page":"e13288","DOI":"10.1111\/bpa.13288","volume":"34","author":"N Straumann","year":"2024","unstructured":"Straumann N, Combes BF, Dean Ben XL, Sternke-Hoffmann R, Gerez JA, Dias I, et al. Visualizing alpha-synuclein and iron deposition in M83 mouse model of Parkinson\u2019s disease in vivo. Brain Pathol. 2024;34(6):e13288.","journal-title":"Brain Pathol"},{"issue":"7","key":"837_CR255","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/nn.2349","volume":"12","author":"Y Li","year":"2009","unstructured":"Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, et al. Mutant LRRK2R1441G BAC Transgenic mice recapitulate Cardinal features of Parkinson\u2019s disease. Nat Neurosci. 2009;12(7):826\u20138.","journal-title":"Nat Neurosci"},{"issue":"7","key":"837_CR256","doi-asserted-by":"publisher","first-page":"e70249","DOI":"10.1371\/journal.pone.0070249","volume":"8","author":"Z Bichler","year":"2013","unstructured":"Bichler Z, Lim HC, Zeng L, Tan EK. Non-Motor and motor features in LRRK2 Transgenic mice. PLoS ONE. 2013;8(7):e70249.","journal-title":"PLoS ONE"},{"key":"837_CR257","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.neuroscience.2012.11.045","volume":"231","author":"M Piltonen","year":"2013","unstructured":"Piltonen M, Savolainen M, Patrikainen S, Baekelandt V, My\u00f6h\u00e4nen TT, M\u00e4nnist\u00f6 PT. Comparison of motor performance, brain biochemistry and histology of two A30P \u03b1-synuclein Transgenic mouse strains. Neuroscience. 2013;231:157\u201368.","journal-title":"Neuroscience"},{"key":"837_CR258","doi-asserted-by":"crossref","unstructured":"Lamontagne-Proulx J, Coulombe K, Morissette M, Rieux M, Calon F, Di Paolo T et al. Sex and age differences in a progressive synucleinopathy mouse model. Biomolecules. 2023;13(6).","DOI":"10.3390\/biom13060977"},{"issue":"1","key":"837_CR259","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41597-021-01054-y","volume":"8","author":"S Forner","year":"2021","unstructured":"Forner S, Kawauchi S, Balderrama-Gutierrez G, Kram\u00e1r EA, Matheos DP, Phan J, et al. Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer\u2019s disease. Sci Data. 2021;8(1):270.","journal-title":"Sci Data"},{"key":"837_CR260","doi-asserted-by":"publisher","first-page":"100078","DOI":"10.1016\/j.nbas.2023.100078","volume":"3","author":"S Smith","year":"2023","unstructured":"Smith S, Hopp SC. The 5XFAD mouse model of Alzheimer\u2019s disease displays age-dependent deficits in habituation to a novel environment. Aging Brain. 2023;3:100078.","journal-title":"Aging Brain"},{"key":"837_CR261","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3233\/JAD-2011-101635","volume":"24","author":"Y Garc\u00eda-Mesa","year":"2011","unstructured":"Garc\u00eda-Mesa Y, L\u00f3pez-Ramos JC, Gim\u00e9nez-Llort L, Revilla S, Guerra R, Gruart A, et al. Physical exercise protects against Alzheimer\u2019s disease in 3xTg-AD mice. J Alzheimers Dis. 2011;24:421\u201354.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"837_CR262","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/cns.12312","volume":"20","author":"S Revilla","year":"2014","unstructured":"Revilla S, Ursulet S, \u00c1lvarez-L\u00f3pez MJ, Castro-Freire M, Perpi\u00f1\u00e1 U, Garc\u00eda-Mesa Y, et al. Lenti-GDNF gene therapy protects against Alzheimer\u2019s disease-like neuropathology in 3xTg-AD mice and MC65 cells. CNS Neurosci Ther. 2014;20(11):961\u201372.","journal-title":"CNS Neurosci Ther"},{"key":"837_CR263","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbr.2015.04.012","volume":"289","author":"KR Stover","year":"2015","unstructured":"Stover KR, Campbell MA, Van Winssen CM, Brown RE. Early detection of cognitive deficits in the 3xTg-AD mouse model of Alzheimer\u2019s disease. Behav Brain Res. 2015;289:29\u201338.","journal-title":"Behav Brain Res"},{"key":"837_CR264","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3389\/fnagi.2018.00250","volume":"10","author":"T Petrasek","year":"2018","unstructured":"Petrasek T, Vojtechova I, Lobellova V, Popelikova A, Janikova M, Brozka H, et al. The McGill Transgenic rat model of Alzheimer\u2019s disease displays cognitive and motor impairments, changes in anxiety and social behavior, and altered circadian activity. Front Aging Neurosci. 2018;10:250.","journal-title":"Front Aging Neurosci"},{"key":"837_CR265","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.neurobiolaging.2017.07.006","volume":"59","author":"MK Edler","year":"2017","unstructured":"Edler MK, Sherwood CC, Meindl RS, Hopkins WD, Ely JJ, Erwin JM, et al. Aged chimpanzees exhibit pathologic hallmarks of Alzheimer\u2019s disease. Neurobiol Aging. 2017;59:107\u201320.","journal-title":"Neurobiol Aging"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00837-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00837-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00837-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:03:00Z","timestamp":1745431380000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00837-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":265,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["837"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00837-w","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}